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Background: There is concern that not all cases of chronic kidney disease (CKD) are known to general practitioners,
leading to an underestimate of its true prevalence. We carried out this study to develop a model to predict the
prevalence of CKD using a large English primary care dataset which includes previously undiagnosed cases of CKD.
Methods: Cross-sectional analysis of data from the Quality Improvement in CKD trial, a representative sample of
743 935 adults in England aged 18 and over. We created multivariable logistic regression models to identify
important predictive factors.
Results: A prevalence of 6.76% was recorded in our sample, compared to a national prevalence of 4.3%. Increasing
age, female gender and cardiovascular disease were associated with a significantly increased prevalence of CKD (p
< 0.001 for all). Age had a complex association with CKD. Cardiovascular disease was a stronger predictive factor in
younger than in older patients. For example, hypertension has an odds ratio of 2.02 amongst patients above
average and an odds ratio of 3.91 amongst patients below average age.
Conclusion: In England many cases of CKD remain undiagnosed. It is possible to use the results of this study to
identify areas with high levels of undiagnosed CKD and groups at particular risk of having CKD.
Trial registration: Current Controlled Trials ISRCTN56023731. Note that this study reports the results of a
cross-sectional analysis of data from this trial.
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Cardiovascular diseaseBackground
Chronic Kidney Disease (CKD) is largely asymptomatic
[1]. Early identification affords opportunities to prevent
and delay disease progression [2]. The potential benefits
of active management include: reducing mortality and
morbidity from cardiovascular diseases; progression to
renal failure amongst patients with proteinuric disease;
improving the quality of life for patients with more severe
symptomatic disease; and reducing the use of resources
and costs for health services [1].
Within England, CKD is included in a national pay-
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reproduction in any medium, provided the ormanagement. However, identification of CKD relies on
opportunistic testing, and there is evidence that not every-
one with CKD is being identified through the P4P scheme.
Data from the Health Survey for England quote a national
prevalence of 6% [3], the corresponding estimate from the
P4P scheme is 4.3% [4]. Because of this difference, mod-
elled estimates of the prevalence of CKD are required to
support case-finding for CKD. These would enable public-
health practitioners to identify and target areas where
there is an under-detection of CKD and hence a need to
promote awareness of its importance and improve existing
local methods for identifying individuals at risk of CKD
such as testing based on currently recommended risk
factors [1].
There are existing models that may be used to esti-
mate the prevalence of CKD for an area [5-8]. However,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from English patients and none check for interactions
between variables.
We carried out this study to create a prevalence model
for CKD. We used routinely collected data and a novel
method to identify patients with CKD that has not been
identified under the P4P scheme [9].
Methods
Data
The Quality Improvement in CKD (QICKD - ISRCTN
56023731) trial [10,11] population includes a representa-
tive large sample of patients with CKD stages 3 to 5 in
England [12]. The primary aim of the QICKD trial is to
compare quality improvement interventions aimed at
lowering systolic blood pressure in patients with CKD in
primary care; ethical approval has been given for second-
ary analyses of the data. Ethics approval was received from
the Oxford Research Ethics Committee (Committee C)
(ref: 07/H0606/141). Here, the QICKD dataset was used
to model the association between the prevalence of CKD
and its potentially explanatory factors. This dataset con-
tained patient-level data, extracted from the computer
systems of 129 English general practices (GP), based in
London, Surrey, Leicester, Birmingham, Cambridge and
Sussex. The full dataset contained information on 930,997
people, of whom 743,935 are aged 18 or over. We only
included people aged 18 or over to be consistent with
the P4P scheme. The data are cross-sectional, extrac-
ted in 2009.
Cases of CKD stages 3 to 5 were strictly defined in ac-
cordance with the 2002 K-DOQI classification [13] on
the basis of an estimated glomerular filtration rate
(eGFR) of less than 60 ml/min/1.73 m2 for at least 90 -
days. Laboratories in England report eGFR using the
four-variable modified diet in renal disease formula [14],
with correction factors applied under the guidance of
the National External Quality Assessment Service [15]
to account for differences in local creatinine assays.
People without a serum creatinine measurement in their
electronic record were assumed for the purposes of the
analysis not to have CKD.
We considered 11 potentially explanatory variables.
These may be loosely classified as socio-demographic
variables and variables about the presence or absence of
cardiovascular disease. The socio-demographic variables
were: age of subject (in years), gender, ethnicity, smoking
status and deprivation score. Ethnicity was based on the
2001 England and Wales Census ‘5 + 1’ categories: ‘Asian’,
‘Black’, ‘Mixed’, ‘White’ ‘Other’, and ‘Not Stated’ [16]. There
were two additional categories: ‘Not recorded’ occurred
when there was an explicit code stating that ethnicity
was not recorded, and ‘Missing’ was for missing ethnicity
data. Smoking status was recorded as ‘never smoked’,‘ex-smoker’, ‘smoker’ or it may be missing Ethnicity
and smoking status were both modelled using dummy
variables. Deprivation score was a continuous variable
from the 2007 index of multiple deprivation [17], and
based on the patient’s postcode [18].
The cardiovascular diseases considered were: diabetes,
ischaemic heart disease (IHD), heart failure, hypertension,
peripheral vascular disease (PVD) and stroke. These were
modelled using dichotomous indicators. Data on systolic
and diastolic blood pressure were available, but were not
used due to high levels of missing data (23% of values
were missing).
Statistical analyses
Multivariable logistic regression was used to model the
dependency of having CKD on the potentially explana-
tory factors. Model building was mainly based on the
recommendations of Hosmer and Lemeshow [19]. Brief-
ly, variables that showed a significant univariate associ-
ation with CKD were included in a multivariable model.
Manual backwards elimination was then applied; drop-
ping non-significant variables one at a time. When no
more variables could be deleted a check was made to see
if any variables could be included. This gave a prelimin-
ary main-effects model. We checked if transformations
were required for any continuous variables in this model,
and considered possible interactions. We only consi-
dered interactions with age as this was known to be a
strong predictor of CKD prevalence [5-7] and important
interactions with age are often identified [20]. We used
sample splitting to validate this approach; the sample
was randomly split into two sub-sets (of approximately
equal size), and the model-building process applied to
both sub-sets.
Due to the large sample size nearly all variables were
statistically significant with p-values less than 0.001. In-
stead we used clinical significance; for our study a vari-
able was defined as clinically significant if its odds ratio
(OR) was either above 1.49 or below 0.67. These values
are derived from published CKD guidelines [1], in which
it is stated that a rise in serum creatinine of over 20%
should be considered significant. We checked for inte-
ractions by plotting the prevalence of CKD against age
and stratifying by the levels of each factor (deprivation
was categorised into quintiles). We observed a non-li-
near interaction between age and the cardiovascular di-
seases. This was modelled by introducing a dummy
variable ‘below age 50’ which takes the value 0 if patients
are below the age of 50 years and 1 otherwise, and in-
cluding its interaction with the cardiovascular diseases.
We constructed a ‘clinical’ model (considering all the
potentially explanatory variables) and a ‘parsimonious’
model which considered just age and gender as it was
noted that sometimes these are the only variables for
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from the full main-effects model, as the use of this is
sometimes recommended in the literature [20,21]. We
used STATA version 10.1 [22] for all analyses.
Missing values for smoking status and ethnicity were
treated as separate categories. Individuals with missing
blood pressure readings (23%) were assumed not to have
hypertension. Missing data for deprivation (19%) were
due to a computer error during data collection, and so
are assumed to be missing completely at random and
were imputed by using a single implementation of the
ICE procedure [23]. There were no missing data for any
of the other variables.
Models were compared based on both their Akaike’s
and the Bayesian information criteria (AIC and BIC
respectively) [24], models with lower values were
preferred. We performed a residual analysis using the
deviance residuals to check goodness of fit. The
Hosmer-Lemeshow test [19] may also be used to for-
mally check goodness of fit. However, this measure is
known to be of limited use for large sample sizes [25],
so a graphical alternative was used: predicted and
observed CKD prevalence were compared using deciles
of predicted values [26,27]. The ability of the models to
correctly classify patients was summarised by their
‘area under the receiver-operating-characteristic curve’
(AUROC) [28], along with their sensitivity, specificity,
positive predictive value and negative predictive value.
These values are known to be biased (give values that
are too optimistic about model performance) when
calculated based on the same data to which the model
was built. To avoid this, we used a model built on one
sub-set of the data, and calculated the statistics on the
remaining sub-set.
Additional analyses
The model-building process was repeated separately for
CKD that had and had not been identified under the
P4P scheme. Descriptive statistics were also produced
for these two CKD classifications.
Results
Of the 743 935 patients, 50 321 had CKD, giving a
prevalence in the adult population of 6.76%. The mean
age of the population was 46.7 years.
Variations in the prevalence of CKD were observed for
all of the potentially explanatory factors (Table 1). With
the exception of gender and the missing levels of both
smoking status and ethnicity, all the univariable odds
ratios are shrunk towards unity when controlled for dif-
ferences in age. This shrinkage is the most notable for
the cardiovascular diseases, for example the univariable
odds ratio for heart failure changes from 16.07 to 2.78
after controlling for age.To reach the clinical model we applied the manual
stepwise method, with the following exception:
 It was not possible to apply clinical significance to
multi-categorical variables (ethnicity and smoking
status). These variables only had one significant level
which related to missing data. After examining
patterns of missing data, it was decided that
smoking (but not ethnicity) data were not missing at
random. Briefly, individuals with missing smoking
status had a very low recorded prevalence for CKD,
all cardiovascular diseases, and were also more likely
to have a missing ethnicity. This suggests that the
observed prevalence amongst subjects with missing
smoking status is biased downwards, possibly due to
a lack of GP contact. The remaining smoking
categories were not clinically significant, and so
smoking status was dropped.
Using the sample splitting approach, the final model in
both sub-sets was the same. Hence these were pooled,
and the model re-estimated based on all of the data.
Summary measures of classification for the model are
based on the sample-splitting approach. For the clinical
model the variables deprivation score, PVD, stroke and
smoking status were excluded.
A graphical check of the functional form for age [19]
indicated that a quadratic term was required. This was
confirmed by residual analysis and was also noticeable in
the graphs constructed to check for interactions with
age (Figure 1). Including the quadratic also reduced both
information criteria.
For all the cardiovascular diseases an interaction with
age was observed which appears to begin at the same
age, two examples are shown in Figure 1. Because of
these consistencies, an interaction with age was included
for every cardiovascular disease in the final clinical
model even though this interaction is only clinically sig-
nificant for hypertension, and is not statistically signifi-
cant for IHD and heart failure. The lack of statistical
significance is likely to be due to the small numbers of
people with the disease who are below average age.
Results for the clinical and the parsimonious model
are presented in Table 2. Increasing age, female gender
and white ethnicity were associated with a significantly
increased prevalence of CKD, as was the presence of
a cardiovascular disease. These cardiovascular diseases
were stronger predictive factors in younger than in older
patients. For example, using the results from the clinical
model, the increases in the odds of CKD due to having
hypertension is 2.02 amongst patients aged over 50 and
3.91 amongst patients aged below 50. Heart failure is
associated with odds of 2.31 in older subjects and 3.14
amongst younger patients.
Table 1 Summary statistics of co-variables used in the analysis
Covariate Sample
Count (%)
Percent
with CKD
Odds ratios*
Uni-variable Bi-variable Multi-variable
Gender
Female 373 929 (50%) 9.12% 1 1 1
Male 370 006 (50%) 4.38% 0.46 0.52 0.48
Ethnicity
Asian 47 439 (6%) 4.31% 0.47 0.80 0.74
Black 34 497 (5%) 3.69% 0.40 0.82 0.77
Mixed 7873 (1%) 4.03% 0.43 1.22 1.17
White 224 806 (30%) 8.82% 1 1 1
Other 12 547 (2%) 2.17% 0.23 0.64 0.69
Not Recorded 8844 (1%) 8.44% 0.95 0.96 1.09
Not Stated 14 780 (2%) 9.53% 1.09 1.70 1.71
Missing 393 149 (53%) 6.21% 0.68 0.73 0.97
Smoking status
Never smoked 357 588 (48%) 7.79% 1 1 1
Ex-smoker 153 051 (21%) 10.93% 1.45 0.970 1.04
Smoker 146 608 (20%) 3.69% 0.45 0.74 0.84
Missing 86 688 (12%) 0.36% 0.04 0.04 0.06
Diabetes
No 708 072 (95%) 5.97% 1 1 1
Yes 35 863 (5%) 22.54% 4.59 1.82 1.47
Stroke
No 728 836 (98%) 6.20% 1 1 1
Yes 15 099 (2%) 34.17% 7.86 1.59 1.27
Heart Failure
No 738 669 (99%) 6.44% 1 1 1
Yes 5266 (1%) 52.51% 16.07 2.78 2.15
Hypertension
No 635 309 (85%) 3.58% 1 1 1
Yes 108 626 (15%) 25.37% 9.15 2.36 1.87
Ischaemic Heart Disease
No 717 929 (97%) 5.80% 1 1 1
Yes 26 006 (4%) 33.35% 8.13 2.77 1.49
Peripheral Vascular Disease
No 738 875 (99%) 6.56% 1 1 1
Yes 5 060 (1%) 36.30% 8.12 1.86 1.44
Mean St. Dev
Age 46.72 18.22 2.51 2.3 to 2.5 2.20
Deprivation 18.36 12.80 0.88 0.96 0.92
* Bivariable odds ratios are from the models including age. Multivariable odds ratios are from the model including all the predictors (constant term, coefficient:
-3.36, 95% CI −3.39 to −3.33). Odds ratios for age are per 10 year increase, for deprivation they are per 10 point increase. Odds ratios in bold indicate values with
a p-value > 0.001.
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Figure 1 Observed prevalence of CKD by age. Results are stratified by diabetes status (left-hand pane) and hypertension status
(right-hand pane).
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suggested that they all fit the data well. There was very
little difference between the in-sample classification
measures, and the out-of sample measures. This suggests
that the optimism due to building and evaluating a mo-
del on the same data is almost neglible for this analysis;
possibly due to the large sample size. Out-of-sample
AUROC scores were 0.898 (full model), 0.898 (clinical
model) and 0.889 (parsimonious model) (Table 3). Graphs
comparing observed and expected deciles of risk were
similar for all three models, only those for the full and
clinical model are shown (Figure 2). These graphs have
been plotted on a log-scale, and show that use of the full
model systematically underestimates CKD prevalence for
this with low prevalence. This bias is mostly removed by
the use of the clinical model, suggesting that it is due to
the omission (in the full model) of the interactions bet-
ween age and cardiovascular diseases.
Applying the model-building process to just patients
with identified CKD gave similar results to using all
cases of CKD, the main difference was the inclusion of
diabetes. However, when it was applied to patients with
unidentified CKD the resulting model was very different.
None of the cardiovascular diseases were clinically sig-
nificant predictors, whilst being of an Asian or Black
ethnicity was a much stronger predictor of not having
CKD (Additional file 1 and Additional file 2). More re-
search is required into why these differences arise.Discussion
We have developed new models to give accurate pre-
dictions of CKD. Increasing age, female gender, white
ethnicity and cardiovascular disease were all associated
with an increased prevalence of CKD. In addition, we
have also shown that there is a complex association with
age which in turn interacts with cardiovascular disease.
The effects of these diseases were greater amongst youn-
ger than older adults. The pattern of this interaction was
very similar for all the cardiovascular diseases.
The results of our study support those previously
published by confirming the important roles of age, gen-
der [5-8,29,30] and CVD [31-33] in predicting cases of
CKD. We also found statistically significant associations
with deprivation and ethnicity, but these were not clini-
cally significant; this may explain why there is weak or
mixed evidence on their importance in predicting the
prevalence of CKD [34].
There are four studies that look at multivariable mo-
dels for predicting the prevalence of CKD [5-8]. ORs for
female varied between 1.19 and 1.49. All four studies
considered the effect of hypertension and diabetes; for
the ORs ranged from 1.4 to 1.72, whilst for the latter ORs
ranged from 0.9 to 2.68. None of the studies considered
interactions between the cardiovascular diseases and age.
Both Bang et al. [5] and Whaley-Connell et al. [7]
considered ethnicity. Bang et al. [5] found that, com-
pared to non-Whites, Whites had a statistically significant
Table 2 Final multivariable logistic regression model for chronic kidney disease
Clinical Parsimonious Clinical
Odds ratio (95% Confidence Interval) P-value**
Age
per 10 years 2.93 (2.85 to 3.02) 3.11 (3.05 to 3.16) <0.001
Age2
per 10 years 0.99 (0.99 to 0.99) 0.99 (0.99 to 1.00) <0.001
Gender
Female* 1 1
Male 0.48 (0.47 to 0.49) 0.52 (0.51 to 0.53) <0.001
Ethnicity
Asian 0.74 (0.70 to 0.78) <0.001
Black 0.72 (0.68 to 0.77) <0.001
Mixed 1.15 (1.01 to 1.31) 0.035
White 1
Other 0.70 (0.61 to 0.80) <0.001
Not Recorded 1.07 (0.98 to 1.16) 0.157
Not Stated 1.67 (1.56 to 1.79) <0.001
Missing 0.85 (0.83 to 0.87) <0.001
Age < 50
No* 1
Yes 1.11 (1.04 to 1.18) 0.002
Heart Failure
No* 1
Yes 2.37 (2.23 to 2.53) <0.001
Yes and <50 1.34 (0.63 to 2.85) 0.45
Hypertension
No* 1
Yes 2.09 (2.05 to 2.14) <0.001
Yes and <50 1.75 (1.59 to 1.92) <0.001
Ischaemic Heart Disease
No* 1
Yes 1.67 (1.61 to 1.72) <0.001
Yes and <50 1.14 (0.81 to 1.60) 0.45
Constant
(Coeffeicient) −3.63 (−3.67 to −3.58) −3.56 (−3.58 to −3.53) <0.001
*Baseline category for odds ratios. Both models fit to 743 935 individuals.
**Wald-based. P-values for age, age2, gender and the constant in the parsimonious models are the same.
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that ethnicity was not a significant predictor in the multi-
variable model. Whaley-Connell et al. [7] considered two
different cohorts; in one White ethnicity was associated
with a statistically significant odds ratio of 1.23 (p < 0.001),
in the other it had a non-significant odds ratio of 0.91
(p = 0.2).
All four studies confirm the important effect of age;
Chadban et al. [6] compared subjects aged under 65 to
those aged over 65 and reported an odds ratio of 102(p < 0.001). The other three studies categorised age, and
reported significant odds ratios for all categories. Our
study further shows that age has a complex association
with CKD.
The results of this model are also consistent with
cohort studies of CKD in showing that there are inte-
ractions between CKD, age and cardiovascular disease
[35]. Other interactions between age and cardiovas-
cular disease have also been reported in the literature
[20,36].
Table 3 Summary measures of the regression models considered
Model/Statistic Main-effects Clinical Parsimonious Clinical; no age2
AIC 248 207 247 771 256 757 248 246
BIC 248 403 248 001 256 803 248 465
DoF 17 18 4 19
In-sample classification measures
Sensitivity 22.05% 17.79% 10.78% 18.91%
Specificity 98.77% 99.07% 99.24% 98.97%
AUROC 0.899 0.899 0.890 0.899
PPV 58.07% 58.29% 50.98% 57.21%
NPV 94.27% 94.30% 93.85% 94.36%
Out-of-sample classification measures
Sensitivity 22.15% 17.76% 10.94% 18.86%
Specificity 98.74% 99.06% 99.24% 98.96%
AUROC 0.898 0.898 0.889 0.898
PPV 57.23% 57.75% 50.88% 56.76%
NPV 94.33% 94.35% 93.91% 94.41%
AIC: Akaike’s Information criteria. BIC: Bayesian information criteria. DoF: Degrees of Freedom. AUROC: Area under the receiver operating characteristic curve.
PPV: Positive predictive value. NPV: Negative predictive value.
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vides multivariable models for predicting the prevalence
of CKD in England. Our results are similar to those
based in other countries in identifying important varia-
bles, but the magnitude of the associations often vary.
For example, we found an odds ratio for female gender
of about two for all three models; a larger value than
that reported in the other studies.Figure 2 Comparison of observed and expected probabilities of havin
model (left-hand pane) and the clinical model (right-hand pane).We have identified important interactions between age
and cardiovascular disease in predicting the prevalence
of CKD. These interaction have not been included in
any of the existing models for predicting the prevalence
of CKD (or in models for predicting the incidence of
CKD [29,30]) despite evidence of its importance in the
literature. Service planning based on existing models,
which fail to capture these interactions, may result in ag CKD, plotted on the log-scale. Results are presented for the full
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in primary and secondary care. More accurate predictions
of CKD prevalence may allow more accurate targeting
of resources toward areas of unmet need. A particular
strength of our study is the large sample size available.
This resulted in increased power to estimate coefficients,
especially for interactions. The large sample size, along
with the consistency of findings when employing sample-
splitting, suggest that the interactions identified in this
study will generalise to the rest of the England CKD
population.
The QICKD study includes patients whose CKD has
not been diagnosed in general practice, and so these
estimates may be compared with the P4P CKD indicator
to determine areas with high levels of un-met need. At a
national level, the P4P indicator in England gives a
prevalence of CKD of 4.3% [4], we reported a prevalence
of 6.76%, suggesting that over a third of people with
CKD are not known to their GP. This confirms findings
in the recent Health Survey for England, which also
included cases of CKD not diagnosed in general and
reported a prevalence of 6% [3]. Analysis of patients with
unidentified CKD suggests that their risk profile may be
different to patients with identified CKD, this is an area
that requires further research.
Limitations
Using cross-sectional data is a limitation, as it is known
that rates of progression vary by patient characteristics
[1]. The results of this analysis may be used to identify
areas with a high prevalence of CKD, where early identi-
fication will be beneficial in reducing both progression
to renal failure and morbidity from cardiovascular dis-
ease. However, when targeting resources for CKD, con-
sideration should also be given to variations in rates of
progression across populations. We also made no dis-
tinction between varying levels of kidney disease. The
available literature suggests that the risk profile for CKD
may vary as kidney disease progresses; for example it has
been shown that the proportion of males with CKD
increases with worsening stage [37], and a recent study
found that non-white ethnicity was a significant pre-
dictor of renal replacement therapy [38]. As renal failure
can be devastating for the patient and very expensive
[1], more research is required into rates of progression.
We have assumed that people without a serum cre-
atinine measurement did not have CKD. Whilst this is
consistent with previous approaches [39], there was no
measurement recorded for 56% of the sample. Hence
the prevalence of CKD reported here is likely to be an
under-estimate.
The choice to use clinical significance instead of statis-
tical significance posed some problems. In particular the
choice of whether or not to include the multi-categoricalvariables ethnicity and smoking status was slightly ar-
bitrary. The importance of all the omitted variables
warrants further research. For the continuous variables
the value of the odds ratio (and hence their clinical sig-
nificance) depends on the units reported. We used the
odds ratio per 10-year increase in age, which is commonly
employed in the literature [5,8,29,30,34]. For deprivation
we used a 10-point increase (deprivation values range bet-
ween 0.75 and 77.37). Using the results from the full
main-effects model, we would need to use a 45-point in-
crease in deprivation for it to become clinically significant,
and a 5-year increase in age for it to become not clinically
significant.
We did not anticipate a priori the nature of the ob-
served interactions between age and the cardiovascular
diseases and this feature needs to be independently con-
firmed. In addition there is scope to improve the mo-
delling of this interaction; noticeably the choice of at
what age to start modelling the interaction warrants fur-
ther research.Conclusions
CKD is largely asymptomatic, making accurate identifi-
cation and subsequent management of patients at risk of
progression difficult. However, identification is important
because progression of patients to symptomatic disease
impairs their quality of life and results in increased costs
for health services. Although included within the P4P
scheme, it is recognised that CKD is under-ascertained
within primary care in England.
We have developed disease prevalence models for CKD
that will allow decision makers to identify areas where the
P4P rates are lower than expected and target these for
possible public health interventions. The results of this
study may also be used to identify sub-groups or patient
profiles in whom the demands for renal services and treat-
ment may be increased, such as young people with a car-
diovascular disease.Additional files
Additional file 1: Summary statistics for the total sample, and for
subjects with chronic kidney disease (CKD), broken-down by
identified and unidentified CKD.
Additional file 2: Full main-effects and ‘clinical’ multivariable
logistic regression models for subjects with identified Chronic
Kidney Disease.Abbreviations
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